AR132377A1 - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- AR132377A1 AR132377A1 ARP240100893A ARP240100893A AR132377A1 AR 132377 A1 AR132377 A1 AR 132377A1 AR P240100893 A ARP240100893 A AR P240100893A AR P240100893 A ARP240100893 A AR P240100893A AR 132377 A1 AR132377 A1 AR 132377A1
- Authority
- AR
- Argentina
- Prior art keywords
- novel compounds
- compounds
- novel
- methods
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos novedosos que tienen la fórmula general (1) en donde R¹, R², R³, A y W son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23167556 | 2023-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132377A1 true AR132377A1 (es) | 2025-06-18 |
Family
ID=86006564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100893A AR132377A1 (es) | 2023-04-12 | 2024-04-10 | Compuestos novedosos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20260092076A1 (es) |
| EP (1) | EP4695243A1 (es) |
| JP (1) | JP2026514037A (es) |
| CN (1) | CN120897918A (es) |
| AR (1) | AR132377A1 (es) |
| TW (1) | TW202506689A (es) |
| WO (1) | WO2024213552A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| CN119431251B (zh) * | 2024-10-24 | 2026-06-19 | 上海凌凯科技股份有限公司 | 一种4-溴-3,6-二氯哒嗪的制备方法 |
| EP4763280A1 (en) * | 2024-12-19 | 2026-06-24 | Lead Discovery Center GmbH | Pharmaceutically active pyrazolo[5,1-c][1,4]benzoxazepine derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021381396A1 (en) * | 2020-11-20 | 2023-06-22 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| EP4330236A4 (en) * | 2021-04-30 | 2025-09-24 | Denali Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
-
2024
- 2024-04-10 EP EP24716408.0A patent/EP4695243A1/en active Pending
- 2024-04-10 CN CN202480024552.8A patent/CN120897918A/zh active Pending
- 2024-04-10 AR ARP240100893A patent/AR132377A1/es unknown
- 2024-04-10 JP JP2025559534A patent/JP2026514037A/ja active Pending
- 2024-04-10 WO PCT/EP2024/059641 patent/WO2024213552A1/en not_active Ceased
- 2024-04-11 TW TW113113542A patent/TW202506689A/zh unknown
-
2025
- 2025-10-07 US US19/351,608 patent/US20260092076A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202506689A (zh) | 2025-02-16 |
| EP4695243A1 (en) | 2026-02-18 |
| WO2024213552A1 (en) | 2024-10-17 |
| CN120897918A (zh) | 2025-11-04 |
| JP2026514037A (ja) | 2026-05-01 |
| US20260092076A1 (en) | 2026-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR131282A1 (es) | Compuestos novedosos | |
| AR131006A1 (es) | Compuestos novedosos | |
| CL2023003312A1 (es) | Inhibidores de nlrp3 | |
| AR130984A1 (es) | Compuestos novedosos | |
| AR123424A1 (es) | Nuevos compuestos heterocíclicos | |
| CL2022001091A1 (es) | Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco (divisional de solicitud 202001871). | |
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| CL2024004085A1 (es) | Compuestos macrocíclicos inhibidores de kras, uso para tratar cáncer. | |
| AR131278A1 (es) | Compuestos novedosos | |
| CO2023016212A2 (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
| CL2022000802A1 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
| AR132456A1 (es) | Compuestos novedosos | |
| CL2023002429A1 (es) | Derivados novedosos de pirimidin-2-il sulfonamida | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| CR20240203A (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| CL2025000126A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CO2025003256A2 (es) | Derivados novedosos deuterados de pirimidin-2-il sulfonamida | |
| CL2025000125A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| UY39173A (es) | Nuevas n-(tetrazol-5-il)- y n-(1,3,4-oxadiazol-2-il)- arilcarboxamidas herbicidas | |
| AR133375A1 (es) | Compuestos novedosos | |
| AR133076A1 (es) | Compuestos novedosos | |
| AR131633A1 (es) | Derivados novedosos de pirimidinil sulfonamida | |
| AR132455A1 (es) | Compuestos novedosos | |
| AR133065A1 (es) | Compuestos de carbolina y uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |